Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Directions in the Therapy of Glioblastoma
Katarzyna Szklener, Marek Mazurek, Małgorzata Wieteska, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5377-5377
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
Vivek Panwar, Aishwarya Singh, Manini Bhatt, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 304
Alternative splicing and related RNA binding proteins in human health and disease
Yining Tao, Qi Zhang, Haoyu Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 70
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 23
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers
Khine Shan, Tauseef Ur Rehman, S. G. Ivanov, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 624-624
Open Access | Times Cited: 10
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Sahil Hussain, Mohd Mursal, Garima Verma, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176484-176484
Closed Access | Times Cited: 10
Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
Weiping Li, Xia Xu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing
T.-J. Kim, Ahwon Lee, Stephen Ahn, et al.
Brain Tumor Research and Treatment (2024) Vol. 12, Iss. 1, pp. 23-23
Open Access | Times Cited: 5
The promise of mitochondria in the treatment of glioblastoma: a brief review
Zhongqiang Liang, Songyun Zhao, Yuankun Liu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
DMC-BH derivative DMC-GF inhibits the growth of glioma stem cells by targeting the TRIM33/SLC25A1/mitochondrial oxidative phosphorylation pathway
Lei Shi, Xifeng Fei, Jian Huang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
KRT80, Regulated by RNF8-Mediated Ubiquitination, Contributes to Glucose Metabolic Reprogramming and Progression of Glioblastoma
Chang Liu, Weiming He, H Zhao, et al.
Neurochemical Research (2025) Vol. 50, Iss. 2
Closed Access
Impact of transducer arrays on deep-seated dosimetry in radiotherapy with concurrent TTFields for glioblastoma (extreme analysis)
Jiajun Zheng, Zhi Wang, Huanfeng Zhu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy
Seyedeh Elham Norollahi, Shahrokh Yousefzadeh-Chabok, Bahman Yousefi, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117137-117137
Closed Access | Times Cited: 4
Are EGFR monoclonal antibodies associated with clinical benefits in patients with glioma: a systematic review, meta-analysis, and specific analysis on glioblastoma and diffuse intrinsic pontine glioma
Mohammad Amin Habibi, Farhang Rashidi, Hossein Gharedaghi, et al.
Neurosurgical Review (2025) Vol. 48, Iss. 1
Closed Access
Dabrafenib and trametinib as a promising treatment option for pediatric population with low-grade gliomas that have BRAF V600E mutation; a breakthrough in the field of neuro-oncology
Zaib Un Nisa Mughal, Tagwa Kalool Fadlalla Ahmad, Abdul Haseeb, et al.
International Journal of Surgery Global Health (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 3
Exposure of human glioblastoma cells to thimerosal inhibits the thioredoxin system and decreases tumor growth-related factors
Isabella Bramatti, Michael Aschner, Vasco Branco, et al.
Toxicology and Applied Pharmacology (2024) Vol. 484, pp. 116844-116844
Open Access | Times Cited: 3
A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer
Zhengzheng Deng, Qiancheng Qing, Bo Huang
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 10, pp. 7255-7272
Closed Access | Times Cited: 3
A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma
Nathaniel Rolfe, Nicholas B. Dadario, Peter Canoll, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 973-973
Open Access | Times Cited: 3
Artificial Intelligence Assists in the Detection of Blood Vessels in Whole Slide Images: Practical Benefits for Oncological Pathology
Anna A. Timakova, Vladislav Ananev, Alexey Fayzullin, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1327-1327
Open Access | Times Cited: 8
C-Myc/H19/miR-29b axis downregulates nerve/glial (NG)2 expression in glioblastoma multiforme
Anne S. Boewe, Selina Wrublewsky, Jessica Hoppstädter, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 1, pp. 102120-102120
Open Access | Times Cited: 2
Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment
Ali Berro, Ahmad Assi, Mohamad Farhat, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104365-104365
Closed Access | Times Cited: 2
The role of IL-17 in the pathogenesis and treatment of glioblastoma—an update on the state of the art and future perspectives
Dariusz Łaszczych, Aleksandra Czernicka, Karol Gostomczyk, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Open Access | Times Cited: 2
Subependymal Giant Cell Astrocytoma: The Molecular Landscape and Treatment Advances
Emanuela Pucko, Dorota Sulejczak, Robert P. Ostrowski
Cancers (2024) Vol. 16, Iss. 19, pp. 3406-3406
Open Access | Times Cited: 2
Novel strategies to overcome chemoresistance in human glioblastoma
Qing Tang, Ting Ren, Peiying Bai, et al.
Biochemical Pharmacology (2024), pp. 116588-116588
Closed Access | Times Cited: 2
Autophagy Inhibition with Chloroquine Increased Pro-Apoptotic Potential of New Aziridine-Hydrazide Hydrazone Derivatives against Glioblastoma Cells
Monika Witusik‐Perkowska, Pola Głowacka, Adam M. Pieczonka, et al.
Cells (2023) Vol. 12, Iss. 14, pp. 1906-1906
Open Access | Times Cited: 5
Research progress on ferroptosis in gliomas (Review)
Yujie Bo, Luyan Mu, Zhao Yang, et al.
Oncology Letters (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top